Immunovant, Inc. Common Stock IMVT
i
Market datapartial · fetched 2026-11-11T13:47:31.897Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T09:01:10.238030312Z
FundamentalsAlpha Vantage · unavailable
Immunovant, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 44.36 | 146.1% | 27.4% | 32.10 | 81.9% | 11.1% |
| 25Δ | 43.18 | 153.0% | 24.9% | 33.15 | 72.2% | 8.5% |
| 30Δ | 33.55 | 82.6% | 8.4% | |||
| 35Δ | 37.61 | 78.9% | 8.7% | 33.95 | 93.0% | 8.2% |
| 40Δ | 36.90 | 76.0% | 7.1% | |||
| 45Δ | 36.31 | 72.9% | 5.9% | 35.23 | 58.9% | 4.1% |
| 50Δ | 35.75 | 73.3% | 5.0% | 35.61 | 53.3% | 3.2% |
| 55Δ | 35.24 | 77.3% | 4.5% | 35.98 | 47.7% | 2.4% |
| 60Δ | 34.68 | 80.0% | 4.0% | 36.48 | 53.1% | 2.2% |
| 65Δ | 34.10 | 81.6% | 3.3% | 36.99 | 59.0% | 2.0% |
| 70Δ | 33.60 | 77.8% | 2.6% | 37.80 | 67.6% | 1.8% |
| 75Δ | 33.11 | 73.0% | 1.9% | 38.19 | 64.5% | 1.5% |
| 80Δ | 31.83 | 90.6% | 1.8% | 38.43 | 57.7% | 1.1% |
20Δ
- Pseudo strike
- 44.36
- IV
- 146.1%
- B/E move
- 27.4%
- Pseudo strike
- 32.10
- IV
- 81.9%
- B/E move
- 11.1%
25Δ
- Pseudo strike
- 43.18
- IV
- 153.0%
- B/E move
- 24.9%
- Pseudo strike
- 33.15
- IV
- 72.2%
- B/E move
- 8.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 33.55
- IV
- 82.6%
- B/E move
- 8.4%
35Δ
- Pseudo strike
- 37.61
- IV
- 78.9%
- B/E move
- 8.7%
- Pseudo strike
- 33.95
- IV
- 93.0%
- B/E move
- 8.2%
40Δ
- Pseudo strike
- 36.90
- IV
- 76.0%
- B/E move
- 7.1%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 36.31
- IV
- 72.9%
- B/E move
- 5.9%
- Pseudo strike
- 35.23
- IV
- 58.9%
- B/E move
- 4.1%
50Δ
- Pseudo strike
- 35.75
- IV
- 73.3%
- B/E move
- 5.0%
- Pseudo strike
- 35.61
- IV
- 53.3%
- B/E move
- 3.2%
55Δ
- Pseudo strike
- 35.24
- IV
- 77.3%
- B/E move
- 4.5%
- Pseudo strike
- 35.98
- IV
- 47.7%
- B/E move
- 2.4%
60Δ
- Pseudo strike
- 34.68
- IV
- 80.0%
- B/E move
- 4.0%
- Pseudo strike
- 36.48
- IV
- 53.1%
- B/E move
- 2.2%
65Δ
- Pseudo strike
- 34.10
- IV
- 81.6%
- B/E move
- 3.3%
- Pseudo strike
- 36.99
- IV
- 59.0%
- B/E move
- 2.0%
70Δ
- Pseudo strike
- 33.60
- IV
- 77.8%
- B/E move
- 2.6%
- Pseudo strike
- 37.80
- IV
- 67.6%
- B/E move
- 1.8%
75Δ
- Pseudo strike
- 33.11
- IV
- 73.0%
- B/E move
- 1.9%
- Pseudo strike
- 38.19
- IV
- 64.5%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 31.83
- IV
- 90.6%
- B/E move
- 1.8%
- Pseudo strike
- 38.43
- IV
- 57.7%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 75.17% | |
| 71.63% | |
| 74.91% | |
| 77.93% | |
| 73.99% | |
| 89.43% | |
| 73.68% | |
| 71.92% | |
| 73.38% | |
| 75.65% | |
| 73.99% | |
| 75.92% | |
| 79.63% | |
| 72.64% | |
| 76.72% | |
| 74.46% | |
| 76.21% | |
| 80.70% | |
| 83.92% | |
| 79.90% | |
| 74.97% | |
| 78.83% | |
| 86.63% | |
| 91.39% | |
| 87.83% | |
| 78.43% | |
| 77.18% | |
| 73.80% | |
| 74.95% | |
| 67.53% | |
| 75.65% | |
| 74.01% | |
| 67.58% | |
| 66.11% | |
| 67.56% | |
| 65.20% | |
| 71.09% | |
| 72.56% | |
| 70.17% | |
| 74.36% | |
| 74.06% | |
| 86.59% | |
| 84.65% | |
| 95.32% | |
| 102.54% | |
| 88.88% | |
| 78.27% | |
| 72.44% | |
| 72.07% | |
| 77.07% | |
| 79.15% | |
| 75.30% | |
| 77.44% | |
| 68.68% | |
| 74.38% | |
| 78.38% |
Biotechnology
INBX
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla,…
More →INCY
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
More →INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic…
More →INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases…
More →INSM
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New…
More →INVA
Description unavailable
More →